Collaborative Arrangements - Reimbursement of R&D Costs (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total reduction to R&D expense	$ 21,262	$ 10,962	$ 82,315	$ 27,769
Mylan
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total reduction to R&D expense	18,638	10,128	75,782	25,869
Alfa Wassermann
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total reduction to R&D expense	2,607	704	6,393	1,493
SciClone Pharmaceuticals
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total reduction to R&D expense	0	0	98	0
R-Pharm
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total reduction to R&D expense	$ 17	$ 130	$ 42	$ 407